Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

详细信息	查看全文 | 推荐本文 |

• 作者：Jonathan M. Meyer ; Vicki G. Davis ; Donald C. Goff ; Joseph P. McEvoy ; Henry A. Nasrallah ; Sonia M. Davis ; Robert A. Rosenheck ; Gail L. Daumit ; John Hsiao ; Marvin S. Swartz ; T. Scott Stroup ; Jeffrey A.
• 关键词：Antipsychotic ; Schizophrenia ; Metabolic syndrome ; Lipids ; HDL ; Triglycerides ; Waist circumference ; Central adiposity
• 刊名：Schizophrenia Research
• 出版年：2008
• 期刊代码：240_09209964
• 类别：med
• 出版时间：April 2008
• 卷：101
• 期：1-3
• 页码：273-286
• 文件大小：490 K

摘要

The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial.